Due to the risk of secondary cancers identified in the IFM-05 trial, long-term monitoring for new symptoms or blood changes is standard practice for those on this regimen.
Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice. IFM_05-May 2022
Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team. Due to the risk of secondary cancers identified
If you are looking for guidance based on this study's results: IFM_05-May 2022
A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.